8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
INCYTE CORP (INCY)

Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY…

Filed with the SEC on · Summarized by InvestorsBot

Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY 2025 financial results for the period ended Dec 31, 2025. Full press release furnished as Exhibit 99.1. 📢 #Earnings #Biotech

Investors: review Incyte’s Feb 10, 2026 press release (Exhibit 99.1) for the detailed Q4 and year‑end 2025 financial metrics — the 8‑K notes the release was furnished under Item 2.02. 🔎 $INCY #SEC #Pharma

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from INCYTE CORP

Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…

8-K · March 26, 2026

Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.

8-K · March 26, 2026

FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…

8-K · March 6, 2026

Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…

8-K · February 10, 2026

Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025.

8-K · December 12, 2025